Generate Biomedicines (GENB)
Builds protein therapeutics through a closed-loop generative-biology platform.
$16.30
Pre-market+0.03 (+0.18%)
At close$16.27(+3.04%)
In millions of USD, except per-share figures
| In millions | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|
| Revenue | 7 | 6 |
| Cost of revenue | 3 | 0 |
| Gross profit | 4 | 6 |
| 68 | 78 | |
| Research & development | 55 | 64 |
| 14 | 14 | |
| General & administrative | 0 | 14 |
| Operating income | −64 | −72 |
| 2 | 4 | |
| Interest income | 3 | 5 |
| Interest expense | 0 | 0 |
| Other non-operating income | 0 | −5 |
| Income before tax | −62 | −67 |
| Income tax expense | 0 | 0 |
| Net income from continuing operations | −62 | −67 |
| Net income | −61 | −67 |
| EPS, basic | −$0.54 | −$0.52 |
| EPS, diluted | −$0.54 | −$0.52 |
| Weighted average shares, basic | 128 | 128 |
| Weighted average shares, diluted | 128 | 128 |
| EBITDA | −61 | −64 |
| Depreciation & amortization | 3 | 3 |
| EBIT | −64 | −67 |